nitroglycerin has been researched along with celecoxib in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 6 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abdellatif, KR; Chen, QH; Chowdhury, MA; Dong, Y; Knaus, EE | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Abdellatif, KR; Chowdhury, MA; Das, D; Dong, Y; Huang, Z; Knaus, EE; Rahman, M; Suresh, MR; Velázquez, CA; Yu, G | 1 |
| Alfonso, S; Anzellotti, P; Anzini, M; Battilocchio, C; Biava, M; Bruno, A; Calderone, V; Di Cesare Mannelli, L; Ghelardini, C; Giordani, A; Giorgi, G; Martelli, A; Papa, G; Patrignani, P; Poce, G; Porretta, GC; Rossi, A; Rovini, M; Sautebin, L; Testai, L; Valenti, S | 1 |
| Anzellotti, P; Anzini, M; Benetti, V; Biava, M; Brogi, S; Calderone, V; Cappelli, A; Chiasserini, L; Di Capua, A; Di Cesare Mannelli, L; Dovizio, M; Ghelardini, C; Giordani, A; Giorgi, G; Giuliani, G; Martelli, A; Pace, S; Patrignani, P; Poce, G; Rossi, A; Rovini, M; Sautebin, L; Sega, A; Testai, L; Valenti, S; Vomero, S | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Duffy, SJ; Eberhardt, RT; Gokce, N; Holbrook, M; Keaney, JF; Maxwell, C; Morrow, JD; Palmisano, J; Price, DT; Vita, JA; Widlansky, ME | 1 |
| Buttgereit, F; Schultz, O | 1 |
| Brzozowski, T; Konturek, SJ; Kwiecien, S; Mazurkiewicz-Janik, M; Pajdo, R; Pawlik, M; Pawlik, WW; Ptak-Belowska, A; Sliwowski, Z | 1 |
1 review(s) available for nitroglycerin and celecoxib
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 trial(s) available for nitroglycerin and celecoxib
| Article | Year |
|---|---|
Short- and long-term COX-2 inhibition reverses endothelial dysfunction in patients with hypertension.
Topics: Adult; Analysis of Variance; Blood Pressure; Brachial Artery; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Double-Blind Method; Endothelium, Vascular; Female; Humans; Hypertension; Isoenzymes; Male; Membrane Proteins; Middle Aged; Nitroglycerin; Prostaglandin-Endoperoxide Synthases; Prostaglandins; Pyrazoles; Sulfonamides; Time Factors; Vasodilation | 2003 |
[Selective COX-2 inhibition improves endothelial function in coronary artery disease].
Topics: Aged; Arteries; Celecoxib; Coronary Artery Disease; Coronary Vessels; Cyclooxygenase 2; Endothelium-Dependent Relaxing Factors; Endothelium, Vascular; Humans; Isoenzymes; Membrane Proteins; Middle Aged; Nitroglycerin; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Recovery of Function; Sulfonamides; Treatment Outcome; Ultrasonography | 2003 |
6 other study(ies) available for nitroglycerin and celecoxib
| Article | Year |
|---|---|
Diazen-1-ium-1,2-diolated and nitrooxyethyl nitric oxide donor ester prodrugs of anti-inflammatory (E)-2-(aryl)-3-(4-methanesulfonylphenyl)acrylic acids: synthesis, cyclooxygenase inhibition, and nitric oxide release studies.
Topics: Acrylates; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2 Inhibitors; Esters; Nitric Oxide; Nitric Oxide Donors; Prodrugs; Rats; Serum; Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Celecoxib analogs possessing a N-(4-nitrooxybutyl)piperidin-4-yl or N-(4-nitrooxybutyl)-1,2,3,6-tetrahydropyridin-4-yl nitric oxide donor moiety: synthesis, biological evaluation and nitric oxide release studies.
Topics: Animals; Anti-Inflammatory Agents; Aspirin; Celecoxib; Crystallography, X-Ray; Cyclooxygenase 2 Inhibitors; Humans; Hydrogen-Ion Concentration; Ibuprofen; Inhibitory Concentration 50; Molecular Structure; Nitric Oxide; Nitric Oxide Donors; Piperidines; Prodrugs; Pyrazoles; Rats; Sheep; Structure-Activity Relationship; Sulfonamides | 2010 |
Novel analgesic/anti-inflammatory agents: diarylpyrrole acetic esters endowed with nitric oxide releasing properties.
Topics: Acetates; Animals; Cell Line; Constriction, Pathologic; Cyclooxygenase 2 Inhibitors; Edema; Esters; Humans; Hyperalgesia; In Vitro Techniques; Isoenzymes; Macrophages; Male; Mice; Models, Molecular; Nitric Oxide Donors; Pyrroles; Rats; Rats, Sprague-Dawley; Rats, Wistar; Structure-Activity Relationship; Vasodilator Agents | 2011 |
Novel analgesic/anti-inflammatory agents: 1,5-diarylpyrrole nitrooxyalkyl ethers and related compounds as cyclooxygenase-2 inhibiting nitric oxide donors.
Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Ethers; Humans; Inhibitory Concentration 50; Mice; Nitric Oxide Donors; Osteoarthritis; Pyrroles; Rats | 2013 |
Nitric oxide (NO)-releasing aspirin exhibits a potent esophagoprotection in experimental model of acute reflux esophagitis. Role of nitric oxide and proinflammatory cytokines.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Cytokines; Dinoprostone; Esophagitis, Peptic; Esophagus; Gastric Acid; Humans; Indomethacin; Male; Nitric Oxide; Nitric Oxide Donors; Nitroglycerin; Pyrazoles; Rats; Rats, Wistar; RNA, Messenger; Sulfonamides | 2011 |